Human CCR4Serial/Model NO. Monoclonal Antibody

  • Favorite
Zoonogen

Business Type:Others

Country/Region:China

Ddu Verified

HOT Rank

6/10

Product Information

Description

Product name

Human CCR4 monoclonal antibody

Catalogue   No.

M100001

Origin/isoform

Human, IgG1a, kappa

Buffer

0.2μM   sterilized PBS, pH7.4

Formulation

Liquid

Specifications

Each   tube contains 100μg Protein A/G purified IgG

Shelf   time

12 months

Storage

-20

Application:

ELISA, FACS,   WB, ADCC

Specificity

Specifically   recognize human CCR4

Epitope:

Conformational/Linear

Notes

CCR4   (C-C chemokine receptor 4) is a 42 kDa member of the GPCR #1 family of   transmembrane proteins. In rodent, functional CCR4 is expressed on fully   differentiated CD4+Th2 cells, invariant CD4+NKT cells,   and neurons. It is the receptor for CCL17/TARC, CCL22/MDC and CKLF1, and   responds to these ligands by initiating chemotaxis. Mouse CCR4 is a   7-transmembrane protein that is 360 amino acids (aa) in length. It contains a   39 aa N-terminal extracellular domain, and a 52 aa C-terminal cyoplasmic tail   that shows a poly-Ser motif between aa 343-346. Over aa sequences 1-39,   99-111, 176-205 and 268-284 collectively, mouse CCR4 shares 85% and 93% aa   identity with human and rat CCR4, respectively. CCR4 is a G protein-linked   seven transmembrane domain chemokine receptor that binds the chemokines   CCL17/TARC and CCL22/MDC. Current evidence suggests that CCR4 expression is   associated with Th-2 type T cells and with platelets. CCR4 expression has   also been reported in mature dendritic cells.

Reference

1.   Lloyd C M, et al. (2000). CC chemokine receptor (CCR) 3/eotaxin is followed   by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte   type 2 recruitment after serial antigen challenge in vivo. The Journal of   experimental medicine. 191(2): 265-274.

2.   Ishida T, et al. (2003). Clinical Significance of CCR4 Expression in Adult   T-Cell Leukemia/Lymphoma Its Close Association with Skin Involvement and   Unfavorable Outcome. Clinical Cancer Research. 9(10): 3625-3634.

 


You Might Also Like
Change a group
Inquiry Cart(0)